VISTAGEN THERAPEUTICS INC
VTGNNASDAQ🏆 #3744 by market capUS Equity
$911.84▲ $64.47 (+7.07%)
Simulated price1h—
24h▲ 7.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
+15.3%
Healthy
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
10.0x
Elevated
Otter Score
65
Fair
No chart data available for VTGN.
Trading Snapshot
- Day Range
- $906.63 – $916.84
- 52-Week Range
- $0.20 – $5.14
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 41.0M
- Next Earnings
- Sep 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $979,530
- Last Q Revenue
- $249,988
- P/E Ratio
- —
- P/S Ratio
- 10.0x
- EPS (TTM)
- $-1.85
- Dividend Yield
- —
Why Investors Own VTGN
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$979,530▲ +22.6% YoY
Gross Margin (TTM)
30.2%▲ +0.2% YoY
Operating Income (TTM)
$128,318▲ +22.6% YoY
Free Cash Flow (TTM)
$219,415▲ +22.6% YoY
About VISTAGEN THERAPEUTICS INC
A company profile for VISTAGEN THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
65/100
Analyst Price Target
ⓘAverage Target
$942.71
▲ +3.4% Upside
High Target$1,114.58
Low Target$715.80
Based on 37 analysts
Latest News & Updates
🚀
Reuters·2h ago
VISTAGEN THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift VTGN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
VISTAGEN THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.